Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord

verfasst von: Hou-bao Fan, Ting Zhang, Kai Sun, Su-pei Song, Shou-bin Cao, Hai-long Zhang, Wen Shen

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Corticotropin-releasing factor (CRF) serves as a neuromodulator in the hypothalamic-pituitary-adrenal axis, playing an essential role in depression, anxiety, and pain regulation. However, its biological role in bone cancer induced pain has not been investigated. In the present study, we aimed to elucidate the expression and distribution of CRF in spinal cord using a rodent model of bone cancer pain. Our study showed that implantation of Walker 256 mammary gland carcinoma cells into the tibia of rats significantly increased CRF expression in the spinal cord in a time-dependent manner. The upregulated expression of CRF mainly expressed in the superficial dorsal horn of spinal cord. Moreover, immunofluorescence double staining showed that CRF was extensively colocalized with neurons, but hardly with astrocytes or microglia. In addition, intrathecal injection of CRF receptor antagonist (α-helical-CRF) significantly inhibited heat hyperalgesia, mechanical allodynia, and the expression of c-Fos in spinal dorsal horn of bone cancer pain rats. In summary, our study demonstrates that CRF plays an important role in the development and maintenance of bone cancer pain via activation of neurons.
Literatur
1.
Zurück zum Zitat Chen L, Zhu L, Wang K, Wang W, Mei XP, Liu T, et al. Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain. Pain Physician. 2013;16:533–46.PubMed Chen L, Zhu L, Wang K, Wang W, Mei XP, Liu T, et al. Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain. Pain Physician. 2013;16:533–46.PubMed
2.
Zurück zum Zitat Gu X, Zheng Y, Ren B, Zhang R, Mei F, Zhang J, et al. Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-alpha expression in a mouse model. Mol Pain. 2010;6:64.CrossRefPubMedPubMedCentral Gu X, Zheng Y, Ren B, Zhang R, Mei F, Zhang J, et al. Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-alpha expression in a mouse model. Mol Pain. 2010;6:64.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, et al. Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. Int J Cancer. 2009;125:1177–85.CrossRefPubMed Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, et al. Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. Int J Cancer. 2009;125:1177–85.CrossRefPubMed
4.
Zurück zum Zitat Luger NM, Mach DB, Sevcik MA, Mantyh PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage. 2005;29:S32–46.CrossRefPubMed Luger NM, Mach DB, Sevcik MA, Mantyh PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage. 2005;29:S32–46.CrossRefPubMed
5.
Zurück zum Zitat Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9.CrossRefPubMed Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9.CrossRefPubMed
6.
7.
Zurück zum Zitat Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–7.CrossRefPubMed Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–7.CrossRefPubMed
9.
Zurück zum Zitat Wang L, Goebel-Stengel M, Stengel A, Wu SV, Ohning G, Tache Y. Comparison of CRF-immunoreactive neurons distribution in mouse and rat brains and selective induction of Fos in rat hypothalamic CRF neurons by abdominal surgery. Brain Res. 2011;1415:34–46.CrossRefPubMedPubMedCentral Wang L, Goebel-Stengel M, Stengel A, Wu SV, Ohning G, Tache Y. Comparison of CRF-immunoreactive neurons distribution in mouse and rat brains and selective induction of Fos in rat hypothalamic CRF neurons by abdominal surgery. Brain Res. 2011;1415:34–46.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Beurel E, Nemeroff CB. Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour. Curr Top Behav Neurosci. 2014;18:67–80.CrossRefPubMedPubMedCentral Beurel E, Nemeroff CB. Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour. Curr Top Behav Neurosci. 2014;18:67–80.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Yu Y, Liu ZQ, Liu XY, Yang L, Geng XR, Yang G, et al. Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance. PLoS One. 2013;8, e65760.CrossRefPubMedPubMedCentral Yu Y, Liu ZQ, Liu XY, Yang L, Geng XR, Yang G, et al. Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance. PLoS One. 2013;8, e65760.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Bangasser DA, Kawasumi Y. Cognitive disruptions in Stress-Related psychiatric disorders: A role for corticotropin releasing factor (CRF). Horm Behav. 2015. Bangasser DA, Kawasumi Y. Cognitive disruptions in Stress-Related psychiatric disorders: A role for corticotropin releasing factor (CRF). Horm Behav. 2015.
13.
Zurück zum Zitat Koob GF, Zorrilla EP. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacol. 2012;37:308–9.CrossRef Koob GF, Zorrilla EP. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view. Neuropsychopharmacol. 2012;37:308–9.CrossRef
14.
Zurück zum Zitat Shippenberg TS, Herz A, Nikolarakis K. Prolonged inflammatory pain modifies corticotropin-releasing factor-induced opioid peptide release in the hypothalamus. Brain Res. 1991;563:209–14.CrossRefPubMed Shippenberg TS, Herz A, Nikolarakis K. Prolonged inflammatory pain modifies corticotropin-releasing factor-induced opioid peptide release in the hypothalamus. Brain Res. 1991;563:209–14.CrossRefPubMed
15.
Zurück zum Zitat Lariviere WR, Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain. 2000;84:1–12.CrossRefPubMed Lariviere WR, Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain. 2000;84:1–12.CrossRefPubMed
16.
Zurück zum Zitat Sekido R, Ishimaru K, Sakita M. Corticotropin-releasing factor and interleukin-1beta are involved in the electroacupuncture-induced analgesic effect on inflammatory pain elicited by carrageenan. Am J Chin Med. 2004;32:269–79.CrossRefPubMed Sekido R, Ishimaru K, Sakita M. Corticotropin-releasing factor and interleukin-1beta are involved in the electroacupuncture-induced analgesic effect on inflammatory pain elicited by carrageenan. Am J Chin Med. 2004;32:269–79.CrossRefPubMed
17.
Zurück zum Zitat Song H, Park H, Park G, Kim YS, Lee HK, Jin DH, et al. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D. Oncol Rep. 2014;32:425–30.PubMed Song H, Park H, Park G, Kim YS, Lee HK, Jin DH, et al. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D. Oncol Rep. 2014;32:425–30.PubMed
18.
19.
Zurück zum Zitat Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–10.CrossRefPubMed Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16:109–10.CrossRefPubMed
20.
Zurück zum Zitat Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006;345:1292–8.CrossRefPubMed Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006;345:1292–8.CrossRefPubMed
21.
Zurück zum Zitat Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–88.CrossRefPubMed Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–88.CrossRefPubMed
22.
Zurück zum Zitat Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, et al. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg. 2012;114:1104–20.CrossRefPubMedPubMedCentral Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, et al. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg. 2012;114:1104–20.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Sande TA, Scott AC, Laird BJ, Wan HI, Fleetwood-Walker SM, Kaasa S, et al. The characteristics of physical activity and gait in patients receiving radiotherapy in cancer induced bone pain. Radiother Oncol. 2014;111:18–24.CrossRefPubMed Sande TA, Scott AC, Laird BJ, Wan HI, Fleetwood-Walker SM, Kaasa S, et al. The characteristics of physical activity and gait in patients receiving radiotherapy in cancer induced bone pain. Radiother Oncol. 2014;111:18–24.CrossRefPubMed
24.
Zurück zum Zitat Currie GL, Delaney A, Bennett MI, Dickenson AH, Egan KJ, Vesterinen HM, et al. Animal models of bone cancer pain: systematic review and meta-analyses. Pain. 2013;154:917–26.CrossRefPubMed Currie GL, Delaney A, Bennett MI, Dickenson AH, Egan KJ, Vesterinen HM, et al. Animal models of bone cancer pain: systematic review and meta-analyses. Pain. 2013;154:917–26.CrossRefPubMed
25.
Zurück zum Zitat Krohg K, Hageman I, Jorgensen MB. Corticotropin-releasing factor (CRF) in stress and disease: a review of literature and treatment perspectives with special emphasis on psychiatric disorders. Nord J Psychiatry. 2008;62:8–16.CrossRefPubMed Krohg K, Hageman I, Jorgensen MB. Corticotropin-releasing factor (CRF) in stress and disease: a review of literature and treatment perspectives with special emphasis on psychiatric disorders. Nord J Psychiatry. 2008;62:8–16.CrossRefPubMed
26.
Zurück zum Zitat Ji G, Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol. 2007;97:3893–904.CrossRefPubMed Ji G, Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol. 2007;97:3893–904.CrossRefPubMed
27.
Zurück zum Zitat Mousa SA, Bopaiah CP, Richter JF, Yamdeu RS, Schafer M. Inhibition of inflammatory pain by CRF at peripheral, spinal and supraspinal sites: Involvement of areas coexpressing CRF receptors and opioid peptides. Neuropsychopharmacol. 2007;32:2530–42.CrossRef Mousa SA, Bopaiah CP, Richter JF, Yamdeu RS, Schafer M. Inhibition of inflammatory pain by CRF at peripheral, spinal and supraspinal sites: Involvement of areas coexpressing CRF receptors and opioid peptides. Neuropsychopharmacol. 2007;32:2530–42.CrossRef
28.
Zurück zum Zitat Kim EH, Ryu DH, Hwang S. The expression of corticotropin-releasing factor and its receptors in the spinal cord and dorsal root ganglion in a rat model of neuropathic pain. Anat Cell Biol. 2011;44:60–8.CrossRefPubMedPubMedCentral Kim EH, Ryu DH, Hwang S. The expression of corticotropin-releasing factor and its receptors in the spinal cord and dorsal root ganglion in a rat model of neuropathic pain. Anat Cell Biol. 2011;44:60–8.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Swiergiel AH, Takahashi LK, Kalin NH. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 1993;623:229–34.CrossRefPubMed Swiergiel AH, Takahashi LK, Kalin NH. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 1993;623:229–34.CrossRefPubMed
30.
Zurück zum Zitat Stern S, Knoll B. CNS axon regeneration inhibitors stimulate an immediate early gene response via MAP kinase-SRF signaling. Mol Brain. 2014;7:86–93.CrossRefPubMedPubMedCentral Stern S, Knoll B. CNS axon regeneration inhibitors stimulate an immediate early gene response via MAP kinase-SRF signaling. Mol Brain. 2014;7:86–93.CrossRefPubMedPubMedCentral
Metadaten
Titel
Corticotropin-releasing factor mediates bone cancer induced pain through neuronal activation in rat spinal cord
verfasst von
Hou-bao Fan
Ting Zhang
Kai Sun
Su-pei Song
Shou-bin Cao
Hai-long Zhang
Wen Shen
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3670-1

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.